比利时社区抗生素消耗监测:报销数据与零售数据的比较(2013—2022年)
本研究比较比利时2013—2022年基层医疗抗生素消耗的报销数据与零售数据,以日均每千居民定义日剂量(DID)表示。抗生素销量从2013年22.89 DID降至2022年20.50 DID,新冠疫情期间从2019年21.31 DID骤降至2020年16.55 DID后反弹。报销数据略低估消耗,相对差异2%—9%,Bland-Altman图显示两法一致性高,喹诺酮类为离群值。
要点
- 抗生素销量从2013年22.89 DID降至2022年20.50 DID,新冠期间2019年21.31 DID降至2020年16.55 DID后反弹。
- 报销数据较零售数据略低估消耗,含喹诺酮类时相对差异2%(2013年)至9%(2022年),不含时为2%至4%。
- Bland-Altman图显示报销与零售估计一致性高,喹诺酮类为离群值。
核心结论
- 研究提示报销数据用于监测抗生素消耗总体可靠,但纳入零售数据对准确评估至关重要,可促进及时干预并为公共卫生策略提供信息。
研究设计与样本
- 研究比较比利时2013—2022年基层医疗抗生素消耗的报销数据(来自国家健康与残疾保险研究所)与零售数据(来自IQVIA)。
- 社区全身用抗生素消耗以日均每千居民定义日剂量(DID,WHO ATC/DDD索引2023版)表示,计算两数据集的DID相对差异(RDs),并通过Bland-Altman图和相关性分析验证。
主要发现
- 抗生素销量从2013年22.89 DID降至2022年20.50 DID。
- 新冠疫情期间抗生素销量从2019年21.31 DID骤降至2020年16.55 DID,随后反弹。
- 报销数据较零售数据略低估消耗,含喹诺酮类时相对差异从2013年2%至2022年9%,不含喹诺酮类时为2%至4%。
- Bland-Altman图显示报销与零售估计一致性高,喹诺酮类为离群值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In Belgium, monitoring antibiotic consumption relies on reimbursement data, which is obtained with a time delay and does not account for over-the-counter or nonreimbursed products. This study aims to bridge this gap by comparing reimbursement and retail data for primary care to understand variations and assess the accuracy of current surveillance methods. METHOD: Reimbursement data were obtained from the National Institute for Health and Disability Insurance, and retail data were obtained from IQVIA for the period 2013-22. The community consumption of systemic antibiotics was expressed in defined daily doses (DDD-WHO ATC/DDD Index 2023) per inhabitants per day (DID). Relative differences in DID (RDs) based on the two data sets were computed and validated through Bland-Altman plots and correlation analysis. RESULTS: The sales of antibiotics declined from 22.89 DID (2013) to 20.50 (2022), with a steep drop during the COVID-19 pandemic-from 21.31 DID in 2019 to 16.55 DID in 2020-and a subsequent rebound. Reimbursement data slightly underestimated consumption compared to retail data, with RDs ranging from 2% (2013) to 9% (2022) when including quinolones and from 2% to 4% when excluding them. Bland-Altman plots showed high agreement between reimbursement and retail estimates, identifying quinolones as outliers. CONCLUSION: Our findings suggest that reimbursement data are generally reliable for monitoring antibiotic consumption, but incorporating retail data is crucial for accurate assessments. The use of retail data can facilitate timely interventions and inform public health strategies to effectively address antimicrobial resistance.
引用
- Damian E, Bonacini L, Kelly M, et al. Monitoring community antibiotic consumption in Belgium: reimbursement versus retail data (2013-22). J Antimicrob Chemother. 2025. PMID: 39450851. doi:10.1093/jac/dkae384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。